Cooley Advises Adamas Pharmaceuticals on Initial Public Offering

San Francisco – April 30, 2014 – Cooley LLP announced today that it advised Adamas Pharmaceuticals, Inc. on its initial public offering. Adamas Pharmaceuticals, a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system, now trades on the NASDAQ Global Stock Market under the symbol "ADMS."

The Cooley corporate and securities team advising Adamas was led by partners Robert Jones and Kenn Guernsey and included partner Danielle Naftulin and associates Seth Gottlieb, Matt Roberts, David Ambler and Katie Stevens. Critical support for the offering was provided by partner Renee Deming and special counsel Jeannie Leahy (compensation & benefits); partner Mark Windfeld-Hansen (tax); partner Natasha Leskovsek (regulatory); partner Michael Tuscan and associate Fraser Brown (intellectual property); and partner Lila Hope and associates Bin Wang and Jennifer Raab (technology transactions).

Thus far in 2014, Cooley has advised on 43 completed public offerings, including 22 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Robert L. Jones Partner, Palo Alto
Kenneth Guernsey Partner, San Francisco
Danielle Naftulin Partner, Palo Alto
Lila Hope Partner, Palo Alto
Michael Tuscan Partner in Charge - Washington, DC
Lawrence Gottlieb Retired Partner, New York
Bin Wang Associate, Beijing
Natasha Leskovsek Partner, Washington, DC
Renee Deming Retired Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Jennifer Raab Associate, Palo Alto
Fraser Brown Partner, Washington, DC
David Ambler Associate, Palo Alto